Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)”In the company’s words, NCT04003857 on ClinicalTrials.gov
- Tested for
- Bronchopulmonary Dysplasia, BPD
- Main trialPhase 2
- “This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age”In the company’s words, NCT04003857 on ClinicalTrials.gov
Other drugs for Bronchopulmonary Dysplasia
- Zelpultide alfaAirway Therapeutics, Inc. · Phase 2/3
- OHB-607OHB Neonatology Ltd. · Phase 2
- Human Umbilical Cord Derived-Mesenchymal Stem CellsMeridigen Biotech Co., Ltd. · Phase 1
Coming up1
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Jun 2027 | Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial | |
| Phase 2Completed | 9 Jan 2024 | PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026